Work

ASO Author Reflections: The Role of Beta-Blockers in Gastric Cancer—A Pathway to Personalized Therapy?

Year: 2025

Type: article

Abstract: PASTChronic stress, via local or systemic inflammation, fosters cancer development by altering immune responses, aggravating key tumor hallmarks, and engaging adrenergic, cholinergic, and neurotrophin signaling, establishing the nervous system as a key tumor microenvironment component.1 Preclinical studies have demonstrated that beta-adrenergic receptor (ADRB) activation promotes tumor growth, resistance to chemotherapy, and increased angiogenesis.Beta-blockers (BB), commonly used for cardiovascular diseases, have been suggested to counteract these effects and improve cancer outcomes.2 Whereas retrospective studies and meta-analyses have shown potential survival benefits and better treatment responses in cancers, such as breast and prostate, evidence in gastric cancer (GC) has been scarce and conflicting.This article refers to: Crnovrsanin N, Zumsande S, Rompen IF, et al.Beta-blockers influence oncological outcomes in gastric cancer patients treated with neoadjuvant chemotherapy based on the pathological subtype: a retrospective cohort study.

Source: Annals of Surgical Oncology

DOI: 10.1245/s10434-025-17326-5